Recently, an analysis of 1763 patient-level data from five randomized trials designed to assess event-free survival in response to TZ, PZ, or both, as part of systemic neoadjuvant and adjuvant therapy for HER2-positive early BC, revealed a lower risk of breast cancer recurrence [7]. The gene discussed is ERBB2; the disease is breast cancer.